Detection of antibodies against feline panleukopenia virus and its application
By optimizing the amino acid sequence of heavy and light chain variable region of cat panleukinenic virus antibodies, we provide detection antibodies with high protein activity and sensitivity specificity, solving the problem of insufficient detection sensitivity and specificity in the prior art, and achieving Efficient specific detection of panleukinin virus in cats.
Patent Information
- Application Number
- CN202310801099.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-30
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-06-30
AI Technical Summary
The prior art cannot effectively detect antibodies to cat panleukinenic virus, and the detection sensitivity and specificity are insufficient, which cannot meet market demand.
Provides cat panleopteropenia virus antibodies with high protein activity and sensitivity specificity for detection methods such as indirect immunofluorescence and indirect ELISA. The heavy and light chain variable region amino acid sequences of the antibodies are optimized to improve their binding affinity. .
It has achieved efficient and specific detection of cat panleukinin virus antibodies, and the binding affinity of the antibodies to recombinantly express FPVVP2 protein has good market application prospects.
Smart Images

Figure BDA0004318078750000141 
Figure BDA0004318078750000151 
Figure BDA0004318078750000161
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biological detection, in particular to an antibody for detecting feline panleukopenia virus and an application thereof. Background Art
[0002] Feline panleukopenia virus (FPV) is also known as feline parvovirus and feline plague virus. Feline infectious enteritis virus belongs to the Parvoviridae family and the Parvovirus genus. It is a single-stranded linear DNA virus. FPV infection is clinically characterized by a sharp decrease in leukocytes, diarrhea, hemorrhagic enteritis, sudden biphasic high fever, dehydration and vomiting. It is currently the most pathogenic and widest range of parvovirus. The virus infection has a high incidence rate and a mortality rate of up to 90%, causing significant harm and economic losses to the global pet industry.
[0003] The FPV genome is composed of non-structural proteins NS1 and NS2 and structural proteins VP1 and VP2. VP2 protein is a relatively conserved antigen-specific capsid protein in FPV. It has important epitopes that stimulate the virus to produce neutralizing antibodies. Mutations in key amino acid sites of VP2 protein play a key role in the pathogenesis of viral infection. It can effectively stimulate the body to produce neutralizing antibodies and affect its pathogenicity, host range and hemagglutination.
[0004] At present, the sensitivity and specificity of diagnostic antibodies for detecting serum antibodies infected with FPV in this field cannot meet the market testing needs. Summary of the invention
[0005] In view of this, the technical problem to be solved by the present invention is to provide antibodies for detecting feline panleukopenia virus and their applications. The present invention provides antibodies for detecting feline panleukopenia virus with high protein activity and more sensitivity and specificity, which can be used for specific detection such as indirect immunofluorescence and indirect ELISA.
[0006] The antibody to feline panleukopenia virus provided by the present invention comprises the following amino acid sequence:
[0007] (1) The three CDR regions of the heavy chain have the amino acid sequences shown in any one of SEQ ID NOs: 1 to 18; the three CDR regions of the light chain have the amino acid sequences shown in any one of SEQ ID NOs: 19 to 36;
[0008] (2) an amino acid sequence that has one or more amino acids substituted, added or deleted from the amino acid sequence shown in (1), but has the same or similar function as the amino acid sequence shown in (1); or
[0009] (3) An amino acid sequence having at least 80% homology with the amino acid sequence shown in (1) or (2).
[0010] In some embodiments, the three CDR regions of the heavy chain of the antibody of the feline panleukopenia virus have the amino acid sequences shown in SEQ ID NOs: 1, 2 and 3, respectively;
[0011] In some embodiments, the three CDR regions of the light chain of the antibody against feline panleukopenia virus have the amino acid sequences shown in SEQ ID NOs: 19, 20 and 21, respectively.
[0012] In the present invention, the antibodies against feline panleukopenia virus include:
[0013] Ⅰ. The four FR regions of its heavy chain have the amino acid sequences shown in any one of SEQ ID NOs: 37 to 60, respectively; the four FR regions of its light chain have the amino acid sequences shown in any one of SEQ ID NOs: 61 to 84, respectively;
[0014] II. An amino acid sequence that has one or more amino acids substituted, added or deleted from the amino acid sequence shown in I, but has the same or similar functions as the amino acids shown in I; or
[0015] III. An amino acid sequence having at least 80% homology with the amino acid sequence shown in I or II.
[0016] In the present invention, the sequence having at least 80% homology is an amino acid sequence obtained by substituting, adding or deleting one or more amino acids on the basis of the original sequence, and the plurality is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36.
[0017] In some embodiments, the four FR regions of the heavy chain of the antibody of feline panleukopenia virus have the amino acid sequences shown in SEQ ID NOs: 37, 38, 39 and 40, respectively;
[0018] In some embodiments, the four FRs of the light chain of the antibody against feline panleukopenia virus have the amino acid sequences shown in SEQ ID NOs: 61, 62, 63 and 64, respectively.
[0019] In some specific embodiments, the heavy chain variable region of the antibody against feline panleukopenia virus comprises the CDR regions shown in SEQ ID NOs: 1, 2 and 3 and the FR regions shown in SEQ ID NOs: 37, 38, 39 and 40.
[0020] In some specific embodiments, the antibody light chain variable region of the feline panleukopenia virus comprises the CDR regions shown in SEQ ID NOs: 19, 20 and 21 and the FR regions shown in SEQ ID NOs: 61, 62, 63 and 64.
[0021] In some embodiments, the heavy chain variable region of the antibody to feline panleukopenia virus has an amino acid sequence as shown in any one of SEQ ID NOs: 85 to 90;
[0022] The antibody light chain variable region of the feline panleukopenia virus has an amino acid sequence as shown in any one of SEQ ID NOs: 91 to 96.
[0023] In some specific embodiments, the heavy chain variable region of the antibody against feline panleukopenia virus has an amino acid sequence as shown in SEQ ID NO: 85; the light chain variable region of the antibody against feline panleukopenia virus has an amino acid sequence as shown in SEQ ID NO: 91.
[0024] In some embodiments, the connecting peptide linker between the heavy chain and the light chain has an amino acid sequence as shown in SEQ ID NO:97.
[0025] In some embodiments, the antibody to feline panleukopenia virus further comprises a constant region, the constant region of the heavy chain is IgGH, and the constant region of the light chain is a κ chain.
[0026] Biomaterial, characterized in that it comprises at least one of the following items I to VI:
[0027] Ⅰ. A nucleic acid encoding an antibody to the feline panleukopenia virus described in any one of the above;
[0028] II. an expression vector comprising the nucleic acid;
[0029] III. transforming or transfecting a host cell with the expression vector;
[0030] IV. A conjugate prepared by coupling the antibody of feline panleukopenia virus with a solid medium or a semisolid medium;
[0031] V. Chemically or biologically labeled antibodies to the feline panleukopenia virus;
[0032] VI. A conjugate prepared by coupling the chemically labeled or biologically labeled antibody against feline panleukopenia virus with a solid medium or a semisolid medium.
[0033] The expression vector of the present invention can express and produce the antibody of feline panleukopenia virus in the host cell, and the host cell is selected from Escherichia coli, yeast, insect cell or mammalian cell.
[0034] The chemical marker is an isotope, an immunotoxin and / or a chemical drug; the biological marker is biotin, avidin or an enzyme marker. The enzyme marker is preferably horseradish peroxidase or alkaline phosphatase. The immunotoxin is preferably aflatoxin, diphtheria toxin, Pseudomonas aeruginosa exotoxin, ricin, abrin, mistletoe agglutinin, radix fasciatus toxin, PAP, herbivorin, gelonin or luffa toxin.
[0035] The solid phase medium or semi-solid medium refers to any support to which the recombinant antibody or labeled recombinant antibody described in the present invention can be attached, including but not limited to nitrocellulose membrane, polyvinylidene fluoride (PVDF) membrane, iPDMS chip, microplate, polystyrene plate, microparticles, microcarriers, gel, etc.
[0036] The present invention provides a method for preparing the antibody, comprising: inducing the expression of the antibody of the feline panleukopenia virus in the host cells in the biological material.
[0037] The present invention provides the use of at least one of the following items ⅰ to ⅲ in the preparation of a detection reagent or a detection kit for feline panleukopenia virus:
[0038] i. Antibodies to the feline panleukopenia virus;
[0039] ii. the biological material;
[0040] iii. Antibodies against feline panleukopenia virus are obtained by the above-mentioned preparation method.
[0041] The present invention provides antibodies for detecting feline panleukopenia virus and applications thereof. The present invention screens out specific antibodies for feline panleukopenia virus by constructing a phage display library. Compared with the prior art, the antibodies for feline panleukopenia virus provided by the present invention have strong specificity, high affinity, can bind to the virus, can be used for specific detection of FPV, and have good market application prospects. The affinity of the antibody was verified by EC50, and the results showed that the EC50 of the binding of the antibodies for feline panleukopenia virus provided by the present invention to the recombinantly expressed FPVVP2 protein was 1.897×10 -1 μg / mL, indicating that the antibody against feline panleukopenia virus has high activity and good affinity. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 The construction of the FPVVP2-scFv phage library and the diversity analysis of the immune library provided in the embodiments of the present invention, wherein (A) the antibody titer detection of New Zealand rabbits immunized 4 times; (B) the amplified bands are the VL gene library and the VH gene library, M: Marker; 1: VH, 2: VL, 3: VL-linker-VH target bands;
[0043] Figure 2 The screening of high-affinity FPVVP2-scFv provided in the embodiment of the present invention, wherein: (A) PCR identification results after electroporation; (B) diversity of the antibody library after the first round of phage display screening; (C) diversity of the antibody library after the second round of phage display screening; (D) the second round of phage ELISA to determine the screening of scFv antibodies with high specificity binding to the antigen FPVVP2;
[0044] Figure 3 The expression and affinity verification of Ab-FPVVP2 provided in the embodiment of the present invention, wherein: (A) SDS-PAGE results of Ab-FPVVP2, M: Marker, 1: Ab-FPVVP2-1, 2: Ab-FPVVP2-2, 3: Ab-FPVVP2-3, 4: Ab-FPVVP2-4, 5: Ab-FPVVP2-5, 6: Ab-FPVVP2-6; (B) EC binding of Ab-FPVVP2-1 antibody to antigen FPVVP2 50 ; (C) EC binding of Ab-FPVVP2-2 antibody to antigen FPVVP2 50 ; (D) EC binding of Ab-FPVVP2-3 antibody to antigen FPVVP2 50 ; (E) EC of Ab-FPVVP2-4 antibody binding to antigen FPVVP2 50 ; (F) EC binding of Ab-FPVVP2-5 antibody to antigen FPVVP2 50 ; (G) EC binding of Ab-FPVVP2-6 antibody to antigen FPVVP2 50 ;
[0045] Figure 4 The results of the indirect immunofluorescence experiment between the Ab-FPVVP2-1 recombinant antibody and the FPV virus provided in the embodiments of the present invention;
[0046] Figure 5 This is the plasmid map of pTT5-V5 and pTT5-V6. DETAILED DESCRIPTION
[0047] The present invention provides antibodies for detecting feline panleukopenia virus and their applications. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0048] The test materials used in the present invention are all common commercial products and can be purchased on the market. Among them:
[0049] Adult New Zealand rabbits were purchased from Yongkang Qingyuan Farm in Dingyuan County, Anhui Province; FPVVP2 protein was prepared and stored by our laboratory (GenBank: M38246.1); FPV virus was stored by our laboratory (GenBank: M38246.1); vectors pTT5-V5 and pTT5-V6 plasmids containing rabbit antibody backbones were stored by our laboratory ( Figure 5 ); HRP-labeled recombinant protein A was purchased from Shanghai Bioengineering Co., Ltd.; HRP-labeled mouse anti-M13K07 phage was purchased from Chengdu Apak Biotechnology Co., Ltd.; HRP-labeled goat anti-rabbit IgG was purchased from Beijing Meikewande Biotechnology Co., Ltd.; pComb3xss plasmid and Escherichia coli DH5α competent cells were purchased from Shandong Hertz Biotechnology Co., Ltd.; M13K07 helper phage and Escherichia coli ER2738 competent cells were purchased from Nanjing Heming Yinggu Biotechnology Co., Ltd.; SDS-PAGE protein gel kit was purchased from Yazyme Biotechnology Co., Ltd.; penicillin-streptomycin solution was purchased from GE (for cell culture); Freund's adjuvant was purchased from Sigma; ClonExpressIIOneStepCloningKit was purchased from Nanjing Novozyme Biotechnology Co., Ltd.; Premixtaq, Plasmidminikit, GelExtraction and transfection reagents were all purchased from TaKaRa.
[0050] The present invention will be further described below in conjunction with embodiments:
[0051] Example 1 Animal Immunization
[0052] Healthy adult New Zealand rabbits were selected for the experiment. Blood was collected from the vein before immunization and the serum was separated as a negative control. 5 TCID 50 / ml FPV virus was injected into the back of the neck of New Zealand rabbits, and immunized once a week for a total of 4 times. 0.5mL of venous blood was collected before each immunization on days 0, 7, 14, and 21 to separate serum for storage. 7 days after the fourth immunization (i.e., day 28), 0.5mL of venous blood was collected to separate serum for storage. ELISA results showed that the serum antibody titer increased significantly 7 days after vaccination, and the antibody titer was greater than 10 after 14 days. 4 , 5×10 after 21 days 4 , after 28 days, it reached 1.28×10 5 ( Figure 1 A). On the 28th day, New Zealand rabbits were sacrificed, 0.5 mL of blood was collected and serum was separated and stored, and the spleen was removed by dissection for lymphocyte separation.
[0053] Example 2 Extraction of total RNA from lymphocytes and amplification of antibody light and heavy chain genes
[0054] The total RNA of lymphocytes was extracted with Trizol reagent, and it was used as a template to synthesize cDNA by reverse transcription using Oligo (dT) as a primer. The primer sequence combination was designed according to the light and heavy chain framework region of the rabbit antibody sequence to PCR amplify the coding region of antibody VH and VL. The PCR reaction conditions were: 95℃ pre-denaturation for 5min, 95℃ denaturation for 30s, 55℃ annealing for 30s, 72℃ extension for 60s, and after 35 cycles, 72℃ extension for another 5min. The PCR product was verified by 1% agarose gel electrophoresis to have a target band around 350bp, and was purified and recovered for use ( Figure 1 B).
[0055] The primer sequence combinations are as follows:
[0056] VH-scFv-F1:
[0057] 5'-GGTGGGGGTGGGTTCCTCTAGATCTTCCCAGTCGKTGGAGGAGTCC-3'
[0058] VH-scFv-F2:
[0059] 5'-GGTGGGGGTGGGTTCCTCTAGATCTTCCCAGWCAGTGAAGGAGTCC-3'
[0060] VH-scFv-F3:
[0061] 5'-GGTGGGGGTGGGTTCCTCTAGATCTTCCCAGTCGCTGGRGGAGTCC-3'
[0062] VH-scFv-F4:
[0063] 5'-GGTGGGGGTGGTTCCTCTAGATCTTCCCAGTCGGTGGAGGAGTCC-3'
[0064] VH-scFv-R1:
[0065] 5'-AGGAGGCTATTGGCCGGCCTGGCCTGARGAGAYGGTGACCAGGGTGCC-3'
[0066] VH-scFv-R2:
[0067] 5'-AGGAGGCTATTGGCCGGCCTGGCCGCAGCAGGGGGCCAGTGGGAAGACTGAC-3'
[0068] VL-scFv-F1:
[0069] 5'-AAAAGAGGCCCAGGCGGCCGAGCTCGTGMTGACCCAGACTCCA-3'
[0070] VL-scFv-F2:
[0071] 5'-AAAAGAGGCCCAGGCGGCCGAGCTCGATMTGACCCAGACTCCA-3'
[0072] VL-scFv-F3:
[0073] 5'-AAAAGAGGCCCAGGCGGCCGCYCAAGTGCTGACCCAG-3'
[0074] VL-scFv-F4:
[0075] 5'-AAAAGAGGCCCAGGCGGCCGCCCWAGTGATGACCCAG-3'
[0076] VL-scFv-R1:
[0077] 5'-GGAAGATCTAGAGGAACCACCCCCACCCGCCCGAGCCACCGCCACCTTTGATTTCCACATTGGTGCC-3'
[0078] VL-scFv-R2:
[0079] 5'-GGAAGATCTAGAGGAACCACCCCCACCACCGCCCGAGCCACCGCCACCTAGGATCTCCAGCTCGGTCCC-3'
[0080] Example 3 Construction of FPVVP2-scFv Antibody Library
[0081] Using purified VH and VL as templates, a linker was inserted between VH and VL after overlapping PCR. The amino acid sequence of the connecting peptide linker was GGGGSGGGGGGSSRSS (SEQ ID NO: 97). The scFv fragment VH-linker-VL was synthesized, and the sequence contained sfiI restriction enzyme sites at both ends.
[0082] Overlap extension first round PCR: without primers, denaturation at 98℃ for 1min, annealing at 45℃ for 30s, extension at 72℃ for 1min, repeat 10 cycles, and finally at 72℃ for 5min. Add primers overlap PCR-FP and overlap PCR-RP, denaturation at 98℃ for 30s, then annealing at 58℃ for 30s, extension at 72℃ for 1min, and after 30 cycles, extend at 72℃ for another 5min. The PCR product was recovered by gel recovery after 1% agarose gel electrophoresis, about 750bp ( Figure 1 B), stored at -20°C. Overlapping PCR primer sequences are as follows:
[0083] Overlap PCR-FP: 5'-GAGGAGGAAAAAGAGGCCCAGGCGGCC-3'
[0084] Overlap PCR-RP: 5'-AGAGGAGGCTATTGGCCGGCCTGGCC-3'
[0085] The PCR product and pComb3XSS vector after gel recovery were digested with restriction endonuclease sfiI at 50°C for 30 minutes. The digestion product was verified by 1% agarose gel electrophoresis, then purified by column recovery and ligated with T4 DNA ligase to obtain the FPVVP2-scFv-pComb3XSS library. The ligation product was transformed into ER2738 competent cells, and positive clones were screened with tetracycline and ampicillin resistant 2YT (2×Yeast extract and Tryptone) solid culture medium. 20 single clones in the library were randomly selected for PCR identification, and the recombination rate of the antibody library was calculated to be 45% ( Figure 2 A). Wash all clones on the solid medium with 2YT medium and store at 4°C. The identification primer sequences are as follows:
[0086] pComb3XSS-FP: 5'-GCTGGTTTCGCTACCGTGGCCCAGGCGGCC-3'
[0087] pComb3XSS-FP: 5'-GTGATGGTGATGGTGCTGGCCGGCCTGGCC-3'
[0088] Example 4 Amplification of bacteriophage
[0089] Take 2 mL of the bacterial library solution of all clones washed with 2YT medium and inoculate it into 50 mL of 2YT liquid medium. Activate at 37°C and 200 rpm until OD 600 When the concentration reaches 0.8-1.0, add the final concentration of 1×10 12 pfu / mL of M13K07 helper phage was used for infection. After standing for 30 minutes, kanamycin (final concentration was 50μg / mL) was added and cultured overnight at 30℃ and 200rpm. The next day, centrifuged at 10000rpm and 4℃ for 20 minutes, retained the supernatant and added 1 / 2 volume of PEG8000 to it, and stood on ice for 2 hours to precipitate the phage. Centrifuged at 10000rpm and 4℃ for 20 minutes, discarded the supernatant. Resuspend the precipitate with 5mL PBS, and add 3mL PEG8000 to re-precipitate. After repeating the centrifugation operation, resuspend the precipitate with 4mL PBS, filter and sterilize, and store at 4℃ for use.
[0090] Example 5 FPVVP2-scFv screening
[0091] Biotinylate the FPVVP2 protein in advance. After mixing the amplified scFv library phage, DynabeadsM-280 magnetic beads labeled with FPVVP2 protein and 2% skim milk powder blocking solution, incubate at 25℃±5℃ for 1h, and wash the magnetic beads with PBST 5-10 times. Elute the phage on the surface of the magnetic beads with 0.1M Glycine-HCl (pH=2.0), and neutralize with 1M Tris to pH 7.0 after elution. Infect ER2738 competent cells in the logarithmic growth phase with the neutralized phage after elution, culture and enrich on 2YT solid medium, and harvest the colonies for the next round of screening.
[0092] The above experiment was repeated twice. 20 monoclones were randomly selected from the two rounds of enrichment affinity screening libraries for PCR verification. The results showed that the positive rate of the constructed FPVVP2-scFv library in the first round of panning was 65%, and the positive rate in the second round of panning was 85% ( Figure 2 B and C).
[0093] Example 6 PhageELISA (single-chain antibody affinity detection)
[0094] Coat the ELISA plate with FPVVP2 antigen at a concentration of 50 μg / mL per well at 4°C overnight. Wash 5 times with PBST solution containing 0.05% Tween-20, discard PBST, add 2% skim milk powder blocking solution, and block at 37°C for 1h. Wash 5 times with PBST solution, pat dry the residual liquid in the well, mix the antibody supernatant to be screened and 2% skim milk powder blocking solution in a ratio of 3:2, stand at 25°C±5°C for 10min to remove interference, add to the ELISA plate, and incubate at 37°C for 1h. Wash 5 times with PBST solution, pat dry the residual liquid in the well, add HRP-labeled mouse anti-M13K07 antibody (diluted 1:3000 with blocking solution), and incubate at 37°C for 1h. The wells were washed five times with PBST solution, the residual liquid in the wells was patted dry, TMB colorimetric solution was added, and after standing in the dark for 15 min, 2 mol / L H2SO4 was added to terminate the color development, and the absorbance at 450 nm was read (the test results are shown in Table 1).
[0095] Table 1 Affinity test of FPVVP2 screening antibodies and antigen FPVVP2
[0096] 0.0491 0.2119 0.3729 0.1299 0.4749 0.9438 0.4844 0.2792 0.3718 0.2723 0.1755 0.1739 0.2612 0.9128 0.1838 0.2363 0.7658 0.1856 0.1295 0.9749 0.0372 0.0847 0.1739 0.2842 0.1849 0.1744 0.2364 0.3947 0.8648 0.2847 0.8758 0.0283 0.084 0.0932 0.3629 0.2745 0.8733 0.1493 0.2848 0.0572 0.2849 0.1947 0.3849 0.1857 0.1085 0.0937 0.2469 0.047 0.1837 0.1395 0.0375 0.3837 0.8274 0.2746 0.3742 0.4848 0.3759 0.3856 0.2845 0.0285 0.2048 0.0385 0.2947 0.3859 0.0639 0.2855 0.7642 0.3038 0.0285 0.2848 0.4274 0.1945 0.2938 0.3927 0.1937 0.1834 0.3287 0.2039 0.0274 0.0948 0.1976 0.2849 0.1639 0.2857 0.1474 0.2353 0.2847 0.0382 0.2842 0.0376 0.0937 0.9547 0.0284 0.3937 0.1739 0.896
[0097] like Figure 2 D display, select OD 450 The 11 antibodies with the highest values were sequenced, and finally 6 antibodies with different sequences were obtained for subsequent experiments.
[0098] Example 7 Recombination, expression and purification of FPVVP2 recombinant antibody Ab-FPVVP2
[0099] The VH and VL sequences of the single-chain antibody scFv were amplified and purified, and the pTT5-V5 and pTT5-V6 vectors containing the rabbit antibody backbone were double-digested with EcoRI and HindIII restriction endonucleases, and the antibody expression plasmids VH-pTT5-V5-1 to VH-pTT5-V5-6 and VL-pTT5-V6-1 to VL-pTT5-V6-6 were obtained by homologous recombination. The recombinant plasmids VH-pTT5-V5-1 to VH-pTT5-V5-6 and VL-pTT5-V6-1 to VL-pTT5-V6-6 were matched one by one and transfected into HEK293f cells by PEI for eukaryotic expression. After 48 hours, the culture supernatant was collected by centrifugation at 10000 rpm and 4°C for 20 minutes, and the antibody was purified using a Protein A affinity chromatography column. Finally, the fusion protein was preserved with PBS solution and named Ab-FPV VP2-1, Ab-FPVVP2-2, Ab-FPVVP2-3, Ab-FPVVP2-4, Ab-FPVVP2-5, and Ab-FPVVP2-6, respectively.
[0100] The sequences of 6 of the antibodies are as follows:
[0101] Heavy chain amino acid sequences of single-chain antibody FPVVP2-scFv-1 and recombinant antibody Ab-FPVVP2-1:
[0102]
[0103] Light chain amino acid sequences of single-chain antibody FPVVP2-scFv-1 and recombinant antibody Ab-FPVVP2-1:
[0104] DGVMTQTPASVSAAVGGTVTIKCQASQSIGSRLAWYQQKAGQRPKLLIYGASTLASGVPSRFRGSGSGTEFTLTISDLECADAATYYCQCNHYGSSYGAAFGGGTEV VVKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC*
[0105] Heavy chain amino acid sequences of single-chain antibody FPVVP2-scFv-2 and recombinant antibody Ab-FPVVP2-2:
[0106]
[0107] Light chain amino acid sequences of single-chain antibody FPVVP2-scFv-2 and recombinant antibody Ab-FPVVP2-2:
[0108] DGDMTQTPASVSEPVGGTVTIKCQASQYISGRLAWYQQKPGQPPKLLIYSASTLASGVPSRFSGSGSGTEFTLTISDLECADAATYYCQCTYYGSTYGGAFGGGTEV VVKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC*
[0109] Heavy chain amino acid sequences of single-chain antibody FPVVP2-scFv-3 and recombinant antibody Ab-FPVVP2-3:
[0110]
[0111] Light chain amino acid sequences of single-chain antibody FPVVP2-scFv-3 and recombinant antibody Ab-FPVVP2-3:
[0112] DGMMTQTPSSKSVPVGDTVTINCQASESVYSNNRLAWYQQKPGQPPKLLIYSASTLASGVPSRFKGSGFGTQFTLTISGVQCDDAATYFCAGYKSSSTAFGGGTEVV VKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC*
[0113] Heavy chain amino acid sequences of single-chain antibody FPVVP2-scFv-4 and recombinant antibody Ab-FPVVP2-4:
[0114]
[0115] Light chain amino acid sequences of single-chain antibody FPVVP2-scFv-4 and recombinant antibody Ab-FPVVP2-4:
[0116] DGVMTQTPSSKSVPVGDTVTINCQASESVYSNNRLAWFQQKPGQPPKLLIYSASTLASGVPSRFKGSGSGTQFTLTISGVQCDDAATYYCAGYKSSSVAFGGGTEVV VKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC*
[0117] Heavy chain amino acid sequences of single-chain antibody FPVVP2-scFv-5 and recombinant antibody Ab-FPVVP2-5:
[0118]
[0119] Light chain amino acid sequences of single-chain antibody FPVVP2-scFv-5 and recombinant antibody Ab-FPVVP2-5:
[0120] DGVMTQTPASVSEPVGGTVTIKCQASQYISSRLAWYQQKPGQPPKLLIYSASTLASGVSSRFKGSGSGTQFTLTISDLECADAATYYCQSTYYTSNVAFGGGTEVV VRGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC*
[0121] Heavy chain amino acid sequences of single-chain antibody FPVVP2-scFv-6 and recombinant antibody Ab-FPVVP2-6:
[0122]
[0123] Light chain amino acid sequences of single-chain antibody FPVVP2-scFv-6 and recombinant antibody Ab-FPVVP2-6:
[0124] DGVMTQTPSSVSAAVGGTVTIKCQASQSIGSSLAWYQQKPGQPPKLLIYRASTLASGVPSRFKGSGSGTQFTLTISDLECADAATYYCQSSYYSGTSSAYGYAFGGGTE VVVKGDPVAPTVLIFPPAADQVATGTVTIVCVANKYFPDVTVTWEVDGTTQTTGIENSKTPQNSADCTYNLSSTLTLTSTQYNSHKEYTCKVTQGTTSVVQSFNRGDC*
[0125] The heavy chain variable regions, light chain variable regions and their corresponding CDR and FR sequences of the six antibodies are shown in Table 2 below.
[0126] Table 2 The amino acid sequences of the heavy chain variable regions, light chain variable regions and their corresponding CDRs and FRs of the six antibodies
[0127]
[0128]
[0129]
[0130] Nucleotide sequences of the heavy chain variable regions of the single-chain antibody FPVVP2-scFv-1 and the recombinant antibody Ab-FPVVP2-1
[0131] 5'-CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGA CACTCACCTGCACCGTCTCTGGATTCTCCCTCAGTAGCTATTCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGATCGGATTCATTAATACTGAGGGTAGCGCATACTACGCGAGCTGGGCAAAAGGCCGATTC ACCATCTCCAGAACTTCGACCACGGTGGATCTGAAAATTCCCAGTCCGACAACCGAGGACACGGCCACCTATTTCTGTGTCAGAGTTAATATTGCTAATTCCGGTGACTTCTGGGGCCAAGGCACCCTGGTCACCGTCTCCTCA-3'
[0132] Nucleotide sequences of light chain variable regions of single-chain antibody FPVVP2-scFv-1 and recombinant antibody Ab-FPVVP2-1
[0133] 5'-GATGGCGTGATGACCCAGACTCCAGCCTCCGTGTCTGCAGCTGTGGGAGGCA CAGTCACCATCAAGTGCCAGGCCAGTCAGAGCATTGGTAGTAGGTTAGCCTGGTATCAGCAGAAAGCAGGGCAGCGTCCCAAGCTCCTGATCTATGGTGCATCCACTCTGGCATCTGGGGTCCCATCGCGGTTCAGGGGC AGTGGATCTGGGACAGAATTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAATGTAATCATTATGGTAGTAGTTATGGTGCTGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA-3'
[0134] Nucleotide sequences of the heavy chain variable regions of the single-chain antibody FPVVP2-scFv-2 and the recombinant antibody Ab-FPVVP2-2
[0135] 5'-CAGTCGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGA CACTCACCTGCACAGTCTCTGGATTCTCCCTCGGTGGCTATGCAATGAATTGGGTCCCGCCAGGCTCCAGGGAAGGGACTGGAATGGATCGGATTGATTAATACTGAAGGTAACACATACTACGCGAACTGGGCGAAAGGCCGATTC ACCATCTCCAAAATCTCGACCACGGTGCATCTGAAAATCACCAGTCCGACAACCGAGGACACGGCCACCTATTTCTGTGCCAGAATAAATGCTGGTAATGCGGCTGACTTGTGGGGCCCAGGCACCCTGGTCACCGTCTCCTCA-3'
[0136] Nucleotide sequences of light chain variable regions of single-chain antibody FPVVP2-scFv-2 and recombinant antibody Ab-FPVVP2-2
[0137] 5’-GATGGCGATATGACCCAGACTCCAGCCTCTGTGTCTGAACCTGTGGGAGGCA CAGTCACCATCAAGTGCCAGGCCAGTCAATACATTAGTGGTAGATTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTATTCTGCGTCCACTCTGGCCTCTGGGGTCCCATCGCGGTTCAGCGGCAGTGGATCTGGGACAGAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAATGTACTTATTATGGTAGTACTTATGGGGGTGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA-3’
[0138] Nucleotide sequences of the heavy chain variable regions of single-chain antibody FPVVP2-scFv-3 and recombinant antibody Ab-FPVVP2-3
[0139] 5’-CAGTCGGTGGAGGAGTCCGGGGGTCGCCTGGTAACGCCTGGAGGATCCCTGA CACTCACCTGCACAGTCTCTGGAATCGACCTCAGTATCTATGAAATGAACTGGGTCCGCCAGGCCCCAGGGAAGGGGCTGGAATGGATCGGAATCATTTATCGTAGGGGTGACACAGACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGACCACGGTGGATCTGAAGTTCACCAGTCCGACAACCGAGGACACGGCCACCTATTTCTGTGCCGCGTTCGATCCTGATACTTATACTTATCCTGCCTTTACTTTGTGGGGCCCAGGCACCCTGGTCACCGTCTCCTCA-3’
[0140] Nucleotide sequences of the light chain variable regions of single-chain antibody FPVVP2-scFv-3 and recombinant antibody Ab-FPVVP2-3
[0141] 5’-GATGGCATGATGACCCAGACACCATCTTCCAAGTCTGTCCCTGTGGGAGACAC AGTCACCATCAATTGCCAGGCCAGTGAGAGTGTTTATAGTAACAACCGCTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTATTCTGCATCCACTCTGGCATCTGGGGTCCCATCGCGGTTCAAAGGCAGTGGATTTGGGACACAGTTCACTCTCACCATCAGCGGCGTGCAGTGTGACGATGCTGCCACTTATTTCTGTGCAGGATATAAAAGTTCTAGTACTGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA-3’
[0142] Nucleotide sequence of the heavy chain variable region of single-chain antibody FPVVP2-scFv-4 and recombinant antibody Ab-FPVVP2-4
[0143] 5’-CAGCAGCAGCTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTAGGACACCC CTGACACTCACCTGCACAGCCTCTGGATTCTCCCTCAGTAGGTATGAAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATGGATCGGAATCATTTATGCTAGTGGTGACACAGACTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAAAACCTCGACCACGGTGGATCTGAAAATGACCAGTCCGACAACCGAGGACACGGCCACCTATTTCTGTGCCAATTTCGATCCTTATGATTATACTTATCCTGCCTTTGGTTTGTGGGGCCCAGGCACCCTGGTCACCGTCTCCTCA-3’
[0144] Nucleotide sequence of the light chain variable region of single-chain antibody FPVVP2-scFv-4 and recombinant antibody Ab-FPVVP2-4
[0145] 5’-GATGGCGTGATGACCCAGACTCCATCTTCCAAGTCTGTCCCTGTGGGAGACACAGTCACCATCAATTGCCAGGCCAGTGAGAGTGTTTATAGTAACAACCGCTTAGCCTGGTTTCAACAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACTCTGCATCCACTCTGGCATCTGGGGTCCCATCGCGGTTCAAAGGCAGTGGATCTGGGACACAGTTCACTCTCACCATCAGCGGCGTGCAGTGTGACGATGCTGCCACTTACTACTGTGCAGGATATAAAAGTAGTAGTGTTGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAAA-3’
[0146] Nucleotide sequence of the heavy chain variable region of single-chain antibody FPVVP2-scFv-5 and recombinant antibody Ab-FPVVP2-5
[0147] 5’-CAGTCGGTGAAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGACACTCACCTGCACAGTCTCTGGATTCTCCCTCAGTAGCTATTCAATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGATTACATCGGATACATTAATACTGATGGTACCACATACTTCGCGACCTGGGCAAAAGGCCGATTCACCATCTCCAAAACCTCGACCACGGTGGATCTGAAAATCACCCGTCCGACAACCGAGGACACGGCCACCTATTTCTGTGCCAGAATTGGAGTTGCTAATAGTGATGATTATTGGGGCCAAGGCACCCTGGTCACCGTCTCCTCA-3’
[0148] Nucleotide sequence of the light chain variable region of single-chain antibody FPVVP2-scFv-5 and recombinant antibody Ab-FPVVP2-5
[0149] 5’-GATGGCGTGATGACCCAGACTCCAGCCTCCGTGTCTGAACCTGTGGGAGGCA CAGTCACCATCAAGTGCCAGGCCAGTCAGTACATTAGTAGTAGATTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTATTCTGCATCCACTCTGGCATCTGGGGTCTCATCGCGGTTCAAAGGCAGTGGATCTGGGACGCAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAATCTACTTATTATACTAGTAATGTTGCTTTCGGCGGAGGGACCGAGGTGGTGGTCAGA-3’
[0150] Nucleotide sequence of the heavy chain variable region of single-chain antibody FPVVP2-scFv-6 and recombinant antibody Ab-FPVVP2-6
[0151] 5’-CAGTCGGTGGAGGAGTCCGGGGGTCGCCTGGTCACGCCTGGGACACCCCTGA CACTCACCTGCACGGTCTCTGGCTTCTCCCTCAGTAGCTATGCAGTGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAATACATCGGAATCATTAATACTGGTGGTACCACATCCTACGCGAGCTGGGCGAAAGGCCGATTCACCATCTCCAGAACCTCGACCACGGTGGATCTGAAAATCCCCAGTCTGACAACCGAGGACACGGCCACCTATTTCTGTGCCAGAGTCCAGTACGATGTTTATGGTTATACTGATACTACCCATGCTTTTGATCCCTGGGGCCCAGGCACCCTGGTCACCGTCTCCTCA-3’
[0152] Nucleotide sequence of the light chain variable region of single-chain antibody FPVVP2-scFv-6 and recombinant antibody Ab-FPVVP2-6
[0153] 5'-GATGGCGTGATGACCCAGACTCCATCCTCTGTGTCTGCAGCTGTGGGAGGCAC AGTCACCATCAAGTGCCAGGCCAGTCAGAGCATTGGTAGTAGCTTAGCCTGGTATCAGCAGAAACCAGGGCAGCCTCCCAAGCTCCTGATCTACAGGGCATCCACTCTGGCATCTGGGGTCCCATCGCGGTTCAAAGGCAGTGG ATCTGGGACACAGTTCACTCTCACCATCAGCGACCTGGAGTGTGCCGATGCTGCCACTTACTACTGTCAAAGCAGTTATTATAGTGGTACTAGTAGTGCTTATGGTTATGCTTTCGCGGAGGGACCGAGGTGGTGGTCAAA-3'
[0154] The purified samples were added to the reduced protein loading buffer and subjected to SDS-PAGE electrophoresis after denaturation. Figure 3 As shown in A, the disulfide bonds between the heavy and light chains of the antibody were reduced, and the target bands were detected at around 50 kDa and 25 kDa, which was consistent with the expected results.
[0155] Example 8 Indirect ELISA method to detect the binding of recombinant antibody Ab-FPVVP2 and FPVVP2 antigen
[0156] The affinity of Ab-FPVVP2 to antigen FPVVP2 was determined by indirect ELISA. Antigen was added to the ELISA plate and incubated at 4°C overnight, and blocked with 2% skim milk powder blocking solution at 37°C for 2h. The antibody was diluted 12 times with 2% skim milk powder and added to the wells, and incubated at 37°C for 1h. HRP-labeled goat anti-rabbit IgG secondary antibody was added, and TMB was used for color development, and the absorbance at a wavelength of 450nm was detected in an ELISA instrument (Tables 3 to 8).
[0157] Detect the binding effect of the above antibody Ab-FPVVP2 as follows Figure 3 As shown in B-3C, the dose-effect curves were successfully fitted with the regression model. All six Ab-FPVVP2 antibodies were able to effectively bind to the FPVVP2 protein. The antibody Ab-FPVVP2-1 had the highest affinity and the EC binding to the recombinantly expressed FPVVP2 protein was 50 is 1.897×10 -1 μg / mL, indicating that the recombinant antibody was active and had good affinity, and Ab-FPVVP2-1 was used in subsequent experiments.
[0158] Table 3 EC binding of Ab-FPVVP2-1 to antigen FPVVP2 50
[0159]
[0160] Table 4 EC binding of Ab-FPVVP2-2 to antigen FPVVP2 50
[0161]
[0162] Table 5 EC50 of Ab-FPVVP2-3 binding to antigen FPVVP2
[0163]
[0164]
[0165] Table 6 EC50 of Ab-FPVVP2-4 binding to antigen FPVVP2
[0166]
[0167] Table 7 EC50 of Ab-FPVVP2-5 binding to antigen FPVVP2
[0168]
[0169] Table 8 EC50 of Ab-FPVVP2-6 binding to antigen FPVVP2
[0170]
[0171] Example 9 Indirect immunofluorescence detection of recombinant antibodies
[0172] Use EMEM containing 10% FBS to revive CRFK adherent cells. When the cell confluency reaches 80-90%, inoculate FPV venom with an MOI of 0.1 and co-infect and culture in a 37°C 5% CO2 incubator. Set up a virus-negative group as a control. Add an equal volume of 2% FBSEMEM and culture in a cell culture incubator. Wash the cells 3 times with PBS after 24 hours. Add 500μL 4% paraformaldehyde to fix the cells, and wash the cells 3 times with PBS after 30 minutes. Add 500μL 0.1% TritonX100, and wash the cells 3 times with PBS after 15 minutes. Block with PBS containing 3% sodium caseinate at 37°C for 1 hour and wash 3 times with PBS. The recombinant antibody Ab-FPVVP2 was used as the primary antibody for indirect immunofluorescence at a concentration of 0.5 μg / mL and incubated at 37°C for 1 h. The secondary antibody was goat anti-rabbit FITC and incubated at 37°C for 1 h. The plate was washed 3 times, 500 ul DAPI was added for staining for 20 min, and the plate was washed 3 times with PBS and observed using an inverted fluorescence microscope. Figure 4 As shown, the recombinant antibody Ab-FPVVP2-1 and FPV virus positive samples showed obvious specific green fluorescence signals, while the virus negative control group showed no fluorescence signals. This proves that the recombinant antibody Ab-FPVVP2 can specifically bind to the FPV virus and can be used for the specific detection of feline panleukopenia virus FPV.
[0173] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. An antibody to feline panleukopenia virus, characterized in that The three CDR regions of the heavy chain include: the amino acid sequence of CDR1 is shown in SEQ ID NO: 1, the amino acid sequence of CDR2 is shown in SEQ ID NO: 2, and the amino acid sequence of CDR3 is shown in SEQ ID NO: 3; The three CDR regions of the light chain include: the amino acid sequence of CDR1 is shown in SEQ ID NO: 19, the amino acid sequence of CDR2 is shown in SEQ ID NO: 20, and the amino acid sequence of CDR3 is shown in SEQ ID NO:
21.
2. The antibody according to claim 1, characterized in that The four FR regions of the heavy chain include: the amino acid sequence of FR1 is shown in SEQ ID NO:37, the amino acid sequence of FR2 is shown in SEQ ID NO:38, the amino acid sequence of FR3 is shown in SEQ ID NO:39, and the amino acid sequence of FR4 is shown in SEQ ID NO:40; The four FR regions of its light chain include: the amino acid sequence of FR1 is shown in SEQ ID NO:61, the amino acid sequence of FR2 is shown in SEQ ID NO:62, the amino acid sequence of FR3 is shown in SEQ ID NO:63, and the amino acid sequence of FR4 is shown in SEQ ID NO:
64.
3. The antibody according to claim 1 or 2, characterized in that Its heavy chain variable region has the amino acid sequence shown in SEQ ID NO:85; The light chain variable region thereof has the amino acid sequence shown in SEQ ID NO:
91.
4. The antibody according to any one of claims 1 to 3, characterized in that The connecting peptide linker between the heavy chain and the light chain has an amino acid sequence as shown in SEQ ID NO:
97.
5. The antibody according to any one of claims 1 to 4, characterized in that It also includes a constant region, the constant region of the heavy chain is IgGH, and the constant region of the light chain is a kappa chain.
6. Biomaterial, characterized in that Include at least one of the following Ⅰ~Ⅵ: Ⅰ. A nucleic acid encoding an antibody against the feline panleukopenia virus according to any one of claims 1 to 5; II. an expression vector comprising the nucleic acid; III. transforming or transfecting a host cell with the expression vector; IV. A conjugate prepared by coupling the antibody against feline panleukopenia virus according to any one of claims 1 to 5 with a solid medium or a semisolid medium; V. A chemically labeled or biologically labeled antibody to the feline panleukopenia virus according to any one of claims 1 to 5; VI. A conjugate prepared by coupling a chemically or biologically labeled antibody against feline panleukopenia virus according to any one of claims 1 to 5 with a solid medium or a semisolid medium.
7. The method for preparing an antibody according to any one of claims 1 to 5, characterized in that: include: Cultivating the host cells in the biomaterial as claimed in claim 6 to induce the expression of antibodies against the feline panleukopenia virus.
8. Use of at least one of the following items ⅰ to ⅲ in the preparation of a detection reagent or a detection kit for feline panleukopenia virus: i. The antibody against feline panleukopenia virus according to any one of claims 1 to 5; ii. The biomaterial according to claim 6; iii. Antibodies against feline panleukopenia virus are obtained by the preparation method according to claim 7.
